Yubo International Biotech Ltd (YBGJ)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

-250K 0 250K 500K 750K Q2 '20: 0 Q3 '20: 0 Q4 '20: 0 Q2 '22: 453.8K Q3 '22: 370K Q4 '22: 104.3K Q1 '23: 245.7K Q2 '23: 239.1K Q3 '23: 653.1K Q4 '23: 608.8K Q1 '24: 455.7K Q2 '24: 454.3K Q3 '24: 25.8K Q4 '24: 3.5K Q1 '25: -18 Q2 '25: -18 Q3 '25: -18 Q4 '25: 12.4K Q1 '26: 12.4K Q2 '26: 12.4K Q3 '20 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

-500K 0 500K 1M 1.5M Q3 '21: 1.4M Q4 '21: 820.6K Q1 '22: 513.3K Q2 '22: 306.2K Q3 '22: 242.6K Q4 '22: 52.7K Q1 '23: 102.1K Q2 '23: 97.1K Q3 '23: 431.6K Q4 '23: 420.7K Q1 '24: 365.7K Q2 '24: 364.8K Q3 '24: 20.7K Q4 '24: 2.6K Q1 '25: -13 Q2 '25: -13 Q3 '25: -13 Q4 '25: 8.2K Q1 '26: 8.2K Q2 '26: 8.2K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income TTM

-2.1M -1.4M -700K 0 700K 1.4M 2.1M Q3 '21: -1.4M Q4 '21: -1.5M Q1 '22: -1.7M Q2 '22: -1.8M Q3 '22: -1.7M Q4 '22: -1.2M Q1 '23: -942.8K Q2 '23: -818.6K Q3 '23: -573.9K Q4 '23: -1.2M Q1 '24: -1.3M Q2 '24: -1.4M Q3 '24: -1.9M Q4 '24: -1.8M Q1 '25: -1.8M Q2 '25: -1.6M Q3 '25: -1.4M Q4 '25: -1.3M Q1 '26: -1.1M Q2 '26: -1.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-2.1M -1.4M -700K 0 700K 1.4M 2.1M Q3 '21: -1.4M Q4 '21: -1.5M Q1 '22: -1.7M Q2 '22: -1.8M Q3 '22: -1.7M Q4 '22: -1.2M Q1 '23: -942.7K Q2 '23: -818.5K Q3 '23: -574.1K Q4 '23: -1.2M Q1 '24: -1.3M Q2 '24: -1.4M Q3 '24: -2M Q4 '24: -1.7M Q1 '25: -1.7M Q2 '25: -1.4M Q3 '25: -1.1M Q4 '25: -1.2M Q1 '26: -990.1K Q2 '26: -1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

-150K 0 150K 300K 450K Q3 '21: 384.9K Q4 '21: 423.7K Q1 '22: 283.9K Q2 '22: 147.6K Q3 '22: 127.5K Q4 '22: 51.6K Q1 '23: 143.6K Q2 '23: 142K Q3 '23: 221.5K Q4 '23: 188.1K Q1 '24: 90K Q2 '24: 89.5K Q3 '24: 5.1K Q4 '24: 822 Q1 '25: -5 Q2 '25: -5 Q3 '25: -5 Q4 '25: 4.2K Q1 '26: 4.2K Q2 '26: 4.2K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow TTM

-1.8M -1.2M -600K 0 600K 1.2M 1.8M Q1 '20: -22K Q4 '21: -1M Q1 '22: 32.7K Q2 '22: -61.2K Q3 '22: 24.9K Q4 '22: -601K Q1 '23: -684.6K Q2 '23: -820K Q3 '23: -870.1K Q4 '23: -739K Q1 '24: -1M Q2 '24: -1.3M Q3 '24: -963.4K Q4 '24: -1.3M Q1 '25: -1.4M Q2 '25: -985.5K Q3 '25: -1.6M Q4 '25: -842.8K Q1 '26: -657.9K Q2 '26: -728K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-1.8M -1.2M -600K 0 600K 1.2M 1.8M Q4 '21: -1.6M Q1 '22: -90.1K Q2 '22: -83.3K Q3 '22: 6.9K Q4 '22: -601K Q1 '23: -694.2K Q2 '23: -820K Q3 '23: -870.1K Q4 '21 Q1 '22 Q2 '22 Q3 '22 Q4 '22 Q1 '23 Q2 '23 Q3 '23

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 60M 120M 180M Q3 '19: 1.2M Q4 '19: 1.2M Q3 '20: 1.2M Q4 '20: 89.7M Q3 '23: 119.8M Q1 '24: 12M Q2 '24: 119.8M Q3 '24: 119.8M Q1 '25: 119.8M Q2 '25: 119.8M Q3 '25: 147.9M Q1 '26: 170.4M Q2 '26: 170.4M Q3 '19 Q3 '20 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.24 -0.16 -0.08 0.00 0.08 0.16 0.24 Q3 '17: -0.21 Q4 '17: -0.21 Q1 '18: -0.12 Q2 '18: -0.12 Q3 '18: -0.12 Q4 '18: -0.11 Q1 '19: -0.13 Q2 '19: -0.12 Q3 '19: -0.12 Q4 '19: -0.12 Q1 '20: -0.11 Q2 '24: -0.09 Q3 '24: -0.10 Q4 '24: -0.02 Q1 '25: -0.02 Q2 '25: -0.02 Q3 '25: -0.01 Q4 '25: 0.00 Q1 '26: 0.00 Q2 '26: 0.00 Q4 '17 Q3 '18 Q2 '19 Q1 '20 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.